Ganirelix

Ganirelix

Clinical data
Pregnancy category	US: X (Contraindicated)
Routes of administration	Subcutaneous injection
ATC code	H01CC01 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	91.1%
Protein binding	81.9%
Elimination half-life	12.8 hours
Excretion	Faecal / Renal (approx. 75%/22%)
Identifiers
CAS Number	123246-29-7 129311-55-3 (diacetate)
DrugBank	APRD00995
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Molar mass	1570.4 g/mol

WikiDoc Resources for Ganirelix
Articles
Most recent articles on Ganirelix Most cited articles on Ganirelix Review articles on Ganirelix Articles on Ganirelix in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ganirelix Images of Ganirelix Photos of Ganirelix Podcasts & MP3s on Ganirelix Videos on Ganirelix
Evidence Based Medicine
Cochrane Collaboration on Ganirelix Bandolier on Ganirelix TRIP on Ganirelix
Clinical Trials
Ongoing Trials on Ganirelix at Clinical Trials.gov Trial results on Ganirelix Clinical Trials on Ganirelix at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ganirelix NICE Guidance on Ganirelix NHS PRODIGY Guidance FDA on Ganirelix CDC on Ganirelix
Books
Books on Ganirelix
News
Ganirelix in the news Be alerted to news on Ganirelix News trends on Ganirelix
Commentary
Blogs on Ganirelix
Definitions
Definitions of Ganirelix
Patient Resources / Community
Patient resources on Ganirelix Discussion groups on Ganirelix Patient Handouts on Ganirelix Directions to Hospitals Treating Ganirelix Risk calculators and risk factors for Ganirelix
Healthcare Provider Resources
Symptoms of Ganirelix Causes & Risk Factors for Ganirelix Diagnostic studies for Ganirelix Treatment of Ganirelix
Continuing Medical Education (CME)
CME Programs on Ganirelix
International
Ganirelix en Espanol Ganirelix en Francais
Business
Ganirelix in the Marketplace Patents on Ganirelix
Experimental / Informatics
List of terms related to Ganirelix

Ganirelix acetate (or diacetate) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in assisted reproduction to control ovulation. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily subcutaneous injection.

Ganirelix is marketed by Organon International as Antagon.

Template:Sex hormones Template:Pituitary and hypothalamic hormones and analogues